Multiple Sclerosis Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged over 18 and up to 50 years old.
- People diagnosed with relapsing-remitting multiple sclerosis (a form of MS with flare-ups followed by periods of recovery) based on the McDonald 2024 diagnostic guidelines.
- People for whom their doctor is considering a change in MS treatment, either because of side effects or personal preference (with no recent signs of MS activity), and who have been on a moderately effective MS medication (such as Interferon beta, Glatiramer acetate, Teriflunomide, Dimethyl fumarate, or Diroximel fumarate) continuously for at least 12 months, or on an anti-S1P therapy (Fingolimod or Ponesimod) continuously for at least 12 months.
- People for whom their doctor is considering a change in MS treatment due to recent signs of MS activity (such as a relapse or new lesions seen on MRI), and who are either new to treatment, have been on a moderately effective MS medication or anti-S1P therapy for at least 6 months, or have been without treatment for at least one year.
- People who have had a brain MRI scan within the past 6 months that includes specific types of imaging sequences used to monitor MS (confirm with trial site).
- People whose MRI scan files are available to be downloaded at the time of their consultation.
- People who are covered by, or are beneficiaries of, a social security system.
- People who are able to give written consent to participate — and, for women who could become pregnant, people who are willing to use an effective form of contraception for the duration of the study, in line with recommended guidelines.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have a progressive form of MS (either primary or secondary progressive MS).
- People who have, or have previously had, another autoimmune disease.
- People who have another serious or uncontrolled health condition apart from active MS.
- People who have been treated with Mitoxantrone, Alemtuzumab, or Cladribine in the three years before joining the trial.
- People who have been treated with Ocrelizumab or Rituximab in the 18 months before joining the trial.
- People who have been treated with Ofatumumab in the 12 months before joining the trial.
- People currently receiving certain high-strength MS medications, including Natalizumab, Ofatumumab, Alemtuzumab, Cladribine, Mitoxantrone, or Ocrelizumab, or Rituximab (S1P receptor modulators are an exception to this rule).
- People currently receiving Mycophenolate mofetil, azathioprine, or cyclophosphamide (Endoxan), or who have previously had a stem cell transplant.
- People already taking part in another clinical trial (whether testing a treatment or not) that could affect the results of this study.
- People who have taken part in a treatment-based clinical trial within the 24 months before joining.
- Women who are pregnant, breastfeeding, or planning to become pregnant during the study.
- People who are under a formal legal protection arrangement, such as guardianship or curatorship.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 02 40 16 52 85
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Treatment choice
Can't join this trial?
Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.